RU2017116966A - Способ удаления ацетальдегида из радиоактивных фармацевтических препаратов - Google Patents
Способ удаления ацетальдегида из радиоактивных фармацевтических препаратов Download PDFInfo
- Publication number
- RU2017116966A RU2017116966A RU2017116966A RU2017116966A RU2017116966A RU 2017116966 A RU2017116966 A RU 2017116966A RU 2017116966 A RU2017116966 A RU 2017116966A RU 2017116966 A RU2017116966 A RU 2017116966A RU 2017116966 A RU2017116966 A RU 2017116966A
- Authority
- RU
- Russia
- Prior art keywords
- radioactive
- composition
- alcohol
- pharmaceutical preparation
- paragraphs
- Prior art date
Links
- 230000002285 radioactive effect Effects 0.000 title claims 13
- 238000000034 method Methods 0.000 title claims 11
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 title claims 4
- 239000003814 drug Substances 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 16
- 239000000203 mixture Substances 0.000 claims 10
- 239000000825 pharmaceutical preparation Substances 0.000 claims 8
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 4
- 238000002600 positron emission tomography Methods 0.000 claims 4
- 239000002904 solvent Substances 0.000 claims 4
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (27)
1. Способ количественного определения, удаления или контроля образования ацетальдегида в фармацевтической композиции, включающий стадию объединения акцептора альдегида с фармацевтической композицией.
2. Способ по п. 1, где акцептор альдегида представляет собой любую молекулу, которая имеет концевую аминооксигруппу.
3. Способ по п. 1, где акцептор альдегида имеет следующую структуру:
4. Способ по любому из пп. 1-3, где лекарственная композиция содержит радиоактивный фармацевтический препарат и растворитель.
5. Способ по п. 4, где радиоактивный фармацевтический препарат представляет собой радиоактивный индикатор для позитронно-эмиссионной томографии (ПЭТ).
6. Способ по п. 5, где радиоактивный фармацевтический препарат представляет собой 18F радиоактивный индикатор для ПЭТ.
7. Способ по п. 6, где радиоактивный фармацевтический препарат выбран из группы соединений, включающей:
8. Способ по любому из пп. 4-7, где растворитель содержит спирт.
9. Способ по п. 8, где указанный спирт выбран из группы, включающей этанол, изопропанол и биоспирт.
10. Способ по п. 9, где указанный спирт представляет собой этанол.
11. Композиция, содержащая акцептор альдегида, радиоактивный фармацевтический препарат и растворитель.
12. Композиция по п. 11, где акцептор альдегида представляет собой любую молекулу, которая имеет концевую аминооксигруппу.
13. Композиция по п. 11, где акцептор альдегида имеет следующую структуру:
14. Композиция по любому из пп. 11-13, где радиоактивный фармацевтический препарат представляет собой радиоактивный индикатор для позитронно-эмиссионной томографии (ПЭТ).
15. Композиция по любому из пп. 11-14, где радиоактивный фармацевтический препарат представляет собой 18F радиоактивный индикатор для ПЭТ.
16. Композиция по п. 15, где радиоактивный фармацевтический препарат выбран из группы соединений, включающей:
17. Композиция по любому из пп. 11-16, где растворитель содержит спирт.
18. Композиция по п. 17, где указанный спирт представляет собой этанол, изопропанол или биоспирт.
19. Композиция по п. 18, где указанный спирт представляет собой этанол.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462087371P | 2014-12-04 | 2014-12-04 | |
| US62/087,371 | 2014-12-04 | ||
| PCT/EP2015/078682 WO2016087653A1 (en) | 2014-12-04 | 2015-12-04 | Method of removing acetaldehyde from radioactive pharmaceuticals |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2017116966A true RU2017116966A (ru) | 2019-01-09 |
| RU2017116966A3 RU2017116966A3 (ru) | 2019-05-14 |
| RU2719399C2 RU2719399C2 (ru) | 2020-04-17 |
Family
ID=55025003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017116966A RU2719399C2 (ru) | 2014-12-04 | 2015-12-04 | Способ удаления ацетальдегида из радиоактивных фармацевтических препаратов |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US10660966B2 (ru) |
| EP (1) | EP3226884B1 (ru) |
| JP (3) | JP6842415B2 (ru) |
| KR (1) | KR102458116B1 (ru) |
| CN (1) | CN106999603B (ru) |
| AU (1) | AU2015356971B2 (ru) |
| IL (1) | IL252186B (ru) |
| RU (1) | RU2719399C2 (ru) |
| WO (1) | WO2016087653A1 (ru) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2719399C2 (ru) | 2014-12-04 | 2020-04-17 | ДжиИ ХЕЛТКЕР ЛИМИТЕД | Способ удаления ацетальдегида из радиоактивных фармацевтических препаратов |
| US11969764B2 (en) | 2016-07-18 | 2024-04-30 | Sortera Technologies, Inc. | Sorting of plastics |
| IT202000012334A1 (it) * | 2020-05-26 | 2021-11-26 | Repi S R L | Formulazione liquida comprendente uno scavenger di aldeidi. |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MC2260A1 (fr) | 1990-06-18 | 1993-04-26 | Dow Chemical Co | Formulations de produits radiopharmaceutiques,leur methode d'administration et leur procede de preparation |
| US5130255A (en) * | 1990-12-13 | 1992-07-14 | Genentech, Inc. | Process for preparing storage stable pharmaceuticals |
| EA200301107A1 (ru) * | 2001-04-13 | 2004-08-26 | Морель, Жан Люк | Способ и устройство для приготовления радиофармацевтических препаратов для инъекций |
| JP2004073377A (ja) * | 2002-08-13 | 2004-03-11 | Takeda Chem Ind Ltd | 固形医薬組成物中の有効成分の安定化方法 |
| JPWO2004037293A1 (ja) * | 2002-10-22 | 2006-02-23 | 大日本住友製薬株式会社 | 安定化組成物 |
| GB0305704D0 (en) | 2003-03-13 | 2003-04-16 | Amersham Plc | Radiofluorination methods |
| GB0410448D0 (en) * | 2004-05-11 | 2004-06-16 | Hammersmith Imanet Ltd | Purification methods |
| GB0420344D0 (en) | 2004-09-14 | 2004-10-13 | Amersham Plc | Diagnostic compounds |
| GB0516564D0 (en) | 2005-08-12 | 2005-09-21 | Ge Healthcare Ltd | Fluorination process |
| PL2182988T3 (pl) | 2007-08-30 | 2015-02-27 | Ge Healthcare Ltd | Kompozycja radiofarmaceutyczna |
| JP5318874B2 (ja) * | 2007-09-10 | 2013-10-16 | ジーイー・ヘルスケア・リミテッド | 放射性フッ素化方法 |
| AU2008324186B2 (en) * | 2007-11-07 | 2014-02-13 | Ge Healthcare Bv | Stabilization of radiopharmaceuticals |
| GB0905328D0 (en) | 2009-03-27 | 2009-05-13 | Ge Healthcare Ltd | Indole derivatives |
| PT2509637T (pt) | 2009-10-08 | 2016-10-05 | Ge Healthcare Ltd | Processo de purificação |
| ES2688574T3 (es) | 2010-03-26 | 2018-11-05 | Ge Healthcare Limited | Derivados de indol tricíclicos como ligandos de PBR |
| JP6055417B2 (ja) * | 2010-12-09 | 2016-12-27 | ジーイー・ヘルスケア・リミテッド | 放射性トレーサー組成物 |
| GB201021263D0 (en) | 2010-12-15 | 2011-01-26 | Ge Healthcare Ltd | Solid phase extraction method |
| GB201202420D0 (en) | 2012-02-13 | 2012-03-28 | Ge Healthcare Ltd | Radiotracer compositions |
| CA2890906A1 (en) * | 2012-11-16 | 2014-05-22 | The Regents Of The University Of California | Pictet-spengler ligation for protein chemical modification |
| RU2719399C2 (ru) | 2014-12-04 | 2020-04-17 | ДжиИ ХЕЛТКЕР ЛИМИТЕД | Способ удаления ацетальдегида из радиоактивных фармацевтических препаратов |
-
2015
- 2015-12-04 RU RU2017116966A patent/RU2719399C2/ru active
- 2015-12-04 KR KR1020177014839A patent/KR102458116B1/ko active IP Right Grant
- 2015-12-04 EP EP15816682.7A patent/EP3226884B1/en active Active
- 2015-12-04 JP JP2017527839A patent/JP6842415B2/ja active Active
- 2015-12-04 AU AU2015356971A patent/AU2015356971B2/en active Active
- 2015-12-04 WO PCT/EP2015/078682 patent/WO2016087653A1/en active Application Filing
- 2015-12-04 US US15/532,938 patent/US10660966B2/en active Active
- 2015-12-04 CN CN201580065805.7A patent/CN106999603B/zh active Active
-
2017
- 2017-05-09 IL IL252186A patent/IL252186B/en active IP Right Grant
-
2020
- 2020-04-15 US US16/849,881 patent/US11389538B2/en active Active
- 2020-11-27 JP JP2020196848A patent/JP7164583B2/ja active Active
-
2022
- 2022-06-13 US US17/838,638 patent/US11964020B2/en active Active
- 2022-10-20 JP JP2022168399A patent/JP7379638B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2017116966A3 (ru) | 2019-05-14 |
| RU2719399C2 (ru) | 2020-04-17 |
| US20170360943A1 (en) | 2017-12-21 |
| CN106999603A (zh) | 2017-08-01 |
| EP3226884B1 (en) | 2021-02-17 |
| KR102458116B1 (ko) | 2022-10-24 |
| JP6842415B2 (ja) | 2021-03-17 |
| JP7379638B2 (ja) | 2023-11-14 |
| EP3226884A1 (en) | 2017-10-11 |
| JP2021063078A (ja) | 2021-04-22 |
| US11389538B2 (en) | 2022-07-19 |
| US11964020B2 (en) | 2024-04-23 |
| IL252186A0 (en) | 2017-07-31 |
| JP2018504369A (ja) | 2018-02-15 |
| AU2015356971B2 (en) | 2021-09-09 |
| US20220305126A1 (en) | 2022-09-29 |
| KR20220148308A (ko) | 2022-11-04 |
| KR20170093132A (ko) | 2017-08-14 |
| US10660966B2 (en) | 2020-05-26 |
| CN106999603B (zh) | 2022-05-27 |
| JP7164583B2 (ja) | 2022-11-01 |
| IL252186B (en) | 2020-04-30 |
| WO2016087653A1 (en) | 2016-06-09 |
| AU2015356971A1 (en) | 2017-06-01 |
| BR112017010484A2 (pt) | 2018-04-03 |
| US20200237921A1 (en) | 2020-07-30 |
| JP2023017790A (ja) | 2023-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015029788A2 (pt) | hetero-multímero, construto de anticorpo isolado, ácido nucleico, célula hospedeira, método para preparar o hetero-multímero, composição farmacêutica, método para tratar uma doença, uso do hetero-multímero, uso de uma quantia terapêutica do hetero-multímero e método para reduzir a função efetora de um construto de anticorpo | |
| JP2014221779A5 (ru) | ||
| AR090903A1 (es) | Anticuerpos e inmunoconjugados anti-pmel17 | |
| AR093377A1 (es) | Anticuerpos anti-notch y conjugados de anticuerpo-farmaco | |
| BR112015023276A2 (pt) | proteína inseticida, molécula de ácido nucleico, construto, célula hospedeira, planta, semente, composição, método para controlar uma população de pragas, método para matar uma praga, método para proteger uma planta, método para produzir um polipeptídeo. | |
| RU2017116966A (ru) | Способ удаления ацетальдегида из радиоактивных фармацевтических препаратов | |
| BR112015022745A2 (pt) | cassete de expressão, célula hospedeira, método de obtenção de célula vegetal, método para controlar uma praga | |
| EP2772859A3 (en) | Configuration data based diagnostic capture | |
| BR112015002566A2 (pt) | sistema de tomografia por emissão de pósitrons (pet), método de tomografia por emissão depósitrons (pet), e meio de armazenamento não transitório legível por computador. | |
| EP2990406A4 (en) | BENZIDINE DERIVATIVE, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION WITH THE BENZIDINE DERIVATIVE FOR THE TREATMENT OF LIVER DISORDERS CAUSED BY THE HEPATITIS C VIRUS | |
| CL2014002248A1 (es) | Composicion farmaceutica que comprende baba de caracol helix aspersa müller (5% a 50%), extracto de manzanilla (5% a 10%) y miel (5% a 10%); procedimiento de preparacion; uso de la composicion porque sirve para preparar un medicamento o dispositivo util para prevenir o tratar lesiones derivadas de la soriasis. | |
| EP2778921A3 (en) | A method and a system for distributed processing of a datasheet | |
| BR112015016112A2 (pt) | dispositivo, sistema e métodos para conectar uma estrutura biológica com pelo menos outra estrutura | |
| ES2598753T3 (es) | Composición farmacéutica para el tratamiento de la tendinitis calcificada y/o bursitis calcificada | |
| CY1121708T1 (el) | Ενωσεις ουριας ινδανυλιου που αναστελλουν την ρ38 map kιναση | |
| Kurita et al. | Validation and application of skeletochronology for age determination of the Ryukyu ground gecko, Goniurosaurus kuroiwae (Squamata: Eublepharidae) | |
| JP2016011272A5 (ru) | ||
| AR106051A1 (es) | Proceso y dispositivo para el pesaje de un animal | |
| Tong et al. | On l-th NMDS Codes | |
| RU2015130359A (ru) | 4-МЕТИЛСУЛЬФАНИЛ ПРОИЗВОДНЫЕ 3,5-ДИМЕТИЛ-1Н-ПИРАЗОЛОВ - АКТИВНЫЕ ВЕЩЕСТВА, ИНГИБИРУЮЩИЕ α-АМИЛАЗУ | |
| ES2560902A2 (es) | Método para la determinación de la intensidad de la modificación de la potencia de un medicamento | |
| ES2517190A1 (es) | Linea celular de carcinoma inflamatorio mamario canino | |
| Park | Justification of the number of animals to be used | |
| RU2016113978A (ru) | Способ количественной оценки приверженности к лечению | |
| KOJIMA | From Soybean and Sorghum to Maize |